Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial

Autor: Diener, H, Agosti, R, Allais, G, Bergmans, P, Bussone, G, Davies, B, Ertas, M, Lanteri Minet, M, Reuter, U, Del Río, MS, Schoenen, J, Schwalen, S, van Oene, J, TOPMAT MIG 303 Investigators Group, C. Lampl, T. Berger, J. Jacquy, L. Herroelen, P. Louis, J. Schoenen, I. Milanov, Z. Zahariev, S. Bozhinov, P. Dočekal, M. Grünermelová, G. Waberžinek, P. Tfelt Hansen, M. Groenbech Jensen, I. Tsiropoulos, R. Kirkeby, M. J. Rasmussen, D. Valade, H. Massiou, C. Sereni, A. Donnet, M. Lanteri Minet, C. Lucas, G. Mick, A. Pradalier, E. Guegan Massardier, H. C. Diener, S. Evers, U. Reuter, A. Straube, D. Mitsikostas, K. Karageorgiou, I. Milonas, G. Georgiadis, G. Gyula, Á. Judit, H. Péter, V. László, O. Hardiman, B. Sweeny, L. Grazzi, B. Colombo, G. Bruzzone, A. Quattrone, C. Benedetto, G. D'Andrea, P. Barbanti, R. De Simone, F. Valguarnera, M. A. Al Jumah, A. Al Tahan, I. Monstad, R. sj, R. Salvesen, LJ Stovner, H. Kwiecinski, W. Fryze, D. Pruchnik Wolinska, R. Motyl, W. Kozubsk, K. Ulatowska Blaszyk, A. Prusinski, L. Cunha, J. Pereira Monteiro, P. Esperança, A. Boyko, A. Skoromets, T. Pogačnik, T. Hojs Fabjan, M. Sánchez Del Río, R. Agosti, F. Donati, B. Tettenborn, M. Siccoli, A. Siva, M. Ertaş, M. Zarifoğlu, B. Davies, P. Davies, D. Bates, M. Fontebasso, P. Cleland, S. Lipscombe, A. Dowson, M. Lawden, S. McPhee, B. Calder, FERRARESE, CARLO

Publikováno v: The Lancet Neurology. 6:1054-1062

BACKGROUND: Use of preventive therapy for migraine is often recommended for only 6-9 months, but no randomised, placebo-controlled trials have investigated migraine frequency after the end of prophylaxis. We assessed the effects of discontinuation of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b22841f260663d94791b83518d646dfe
https://doi.org/10.1016/s1474-4422(07)70272-7

Rapid efficacy of highly active antiretroviral therapy in a case of HIV myelitis

Autor: D. Séréni, C Lamotte, L. Michou, C. Sauve, A Maillard, C Sereni

Publikováno v: European journal of internal medicine. 13(1)

An HIV-seropositive patient with severe immunodepression was diagnosed as having HIV myelitis. Plasma and cerebrospinal fluid (CSF) HIV-RNA PCR were, respectively, 4.11 and 5.19 log 10 . After 1 month of treatment with highly active antiretroviral th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbdd435f839b8ccda062ea9649528877
https://pubmed.ncbi.nlm.nih.gov/11836085

[Contribution of imaging to the diagnosis of the dementias]

Autor: C, Sereni

Publikováno v: Soins; la revue de reference infirmiere. (567)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fc17fd1917331b012d9738f58fd272a0
https://pubmed.ncbi.nlm.nih.gov/1343406

A - 2 Réapparition d’une épilepsie absence après introduction d’un traitement par pregabaline

Autor: M. Aghasaryan, J.-F. Chermann, C. Sereni

Publikováno v: Revue Neurologique. 163:145

Introduction Le Pregabaline est un nouveau medicament utilise dans les douleurs neuropathiques et dans l’epilepsie partielle en association avec les autres antiepileptiques. Observation Une femme âgee de 43 ans fut hospitalisee pour une algie faci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2648da17f5056c1eae0b6eab16ec613f
https://doi.org/10.1016/s0035-3787(07)90767-5

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.